Small-cell lung cancer in England: trends in survival and chemotherapy using the National Lung Cancer Audit.

ABSTRACT:

Background

The purpose of this study was to identify trends in survival and chemotherapy use for individuals with small-cell lung cancer (SCLC) in England using the National Lung Cancer Audit (NLCA).

Methods

We used data from the NLCA database to identify people with histologically proven SCLC from 2004-2011. We calculated the median survival by stage and assessed whether patient characteristics changed over time. We also assessed whether the proportion of patients with records of chemotherapy and/or radiotherapy changed over time.

Results

18,513 patients were diagnosed with SCLC in our cohort. The median survival was 6 months for all patients, 1 year for those with limited stage and 4 months for extensive stage. 69% received chemotherapy and this proportion changed v

SUBMITTER: Khakwani A 

PROVIDER: S-EPMC3931780 | biostudies-literature | 2014

REPOSITORIES: biostudies-literature